World Orphan Drug Congress USA focusses on the most pressing challenges and opportunities to bring rare disease therapies to patients faster.
Walter Colasante, Vice President in the Life Sciences Practice, will be speaking on “Value assessment is different for Rare Diseases, requiring new thinking to build consensus around access decisions” and Charles River Associates is a silver sponsor at this year’s conference.
For more information on this event, click here.
CRA Insights: Life Sciences
CRA’s Life Sciences Litigation team provides periodic summaries of notable developments in litigation. In this issue, we share an update on a Supreme Court...